Year-to-date low. On the 15th, operating profit for the first quarter (24/1-3) of the fiscal year ending 24/12 was disclosed as 2.283 billion yen, etc., up 474.4% from the same period last year, and purchases took precedence the next morning, but profit-taking sales continued thereafter. Albinus and Pfizer in the United States have published the latest clinical data to evaluate combination therapy with oral estrogen receptor-degrading agents targeting breast cancer, and it seems that concerns that they may compete with the GNI Group pipeline are also serious.
ＧＮＩ---年初来安値、利益確定売り続く、パイプライン競合の懸念も
GNI--- year-to-date low, profit margin sales continue, pipeline competition concerns
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.